Key result
Valsartan blocks Angiotensin II-induced macrophage ABCA1 repression and atherosclerosis via Fra2 in mice.
Answers are grounded in this paper and cite their sources.
Angiotensin II (Ang II) is a powerful accelerator of atherosclerosis. Herein, we describe a novel transcription mechanism through which Ang II inhibits macrophage expression of the ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport. We demonstrate that chronic Ang II infusion substantially promotes macrophage infiltration, foam cell formation, and atherosclerosis in low-density lipoprotein receptor-deficient mice and significantly reduces ABCA1 expression in peripheral macrophages. Administration of the Ang II type 1 receptor blocker valsartan inhibited Ang II-induced ABCA1 mRNA repression, macrophage cholesterol accumulation, and atherosclerosis. Ang II treatment reduced ABCA1 promoter activity of in vitro cultured mouse peritoneal macrophages, inducing fos-related antigen 2 (Fra2) protein binding to an ABCA1 promoter E-box motif, a site known to negatively regulate macrophage ABCA1 transcription. Valsartan pretreatment blocked Fra2 binding to the ABCA1 promoter, and Fra2 small interfering RNA pretreatment attenuated Ang II-mediated ABCA1 transcriptional inhibition, confirming the role of Fra2 in this process. This new evidence suggests that Ang II, a well-known proinflammatory and pro-oxidative factor, alters macrophage cholesterol homeostasis by repressing ABCA1 to promote foam cell formation and atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Takata et al. (2005) studied Atherosclerosis. Angiotensin II and valsartan was evaluated on Macrophage ABCA1 expression, foam cell formation, and atherosclerosis. Angiotensin II repressed macrophage ABCA1 transcription via Fra2 to promote foam cell formation and atherosclerosis in mice, an effect inhibited by valsartan.
Synapse has enriched 5 related papers. Consider them for comparative context: